Hepatocellular carcinoma: towards personalized medicine. (Q37984653)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Hepatocellular carcinoma: towards personalized medicine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

main subject

personalized medicine

1 reference

inferred from title

hepatocellular carcinoma

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Kazuaki Chayama

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Hiroshi Aikata

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Hidenori Ochi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

C Nelson Hayes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

15 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

846-850

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Variation of gene-based SNPs and linkage disequilibrium patterns in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

A HapMap harvest of insights into the genetics of common disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

A haplotype map of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Genomic and personalized medicine: foundations and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Hepatitis C pharmacogenetics: state of the art in 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Hepatocellular carcinoma: A global view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Molecular mechanisms of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Hepatocellular carcinoma: recent trends in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Hepatocellular carcinoma in the Asia pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Impact of interleukin-1beta genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Interaction between interleukin-1beta -31T/C gene polymorphism and drinking and smoking habits on the risk of hepatocellular carcinoma among Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Polymorphisms of interleukin-1beta in Japanese patients with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Prevalence of common HFE and SERPINA1 mutations in patients with hepatocellular carcinoma in a Moroccan population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCV-infected Moroccan patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Manganese superoxide dismutase dimorphism and iron overload, hepatocellular carcinoma, and death in hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

FAS promoter polymorphisms correlate with activity grade in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Genomewide association studies and assessment of the risk of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

American Gastroenterological Association technical review on the management of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Conformational stability studies of the pleckstrin DEP domain: definition of the domain boundaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

NCCN clinical practice guidelines in oncology: hepatobiliary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

High-resolution characterization of a hepatocellular carcinoma genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2012.02242.X

Aging of patients with hepatitis C virus-associated hepatocellular carcinoma: long-term trends in Japan.

21 January 2018

1 reference

12 December 2020

Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C.

1 reference

12 December 2020

MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C

1 reference

12 December 2020

Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma

1 reference

12 December 2020

Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma

1 reference

12 December 2020

10.1111/J.1349-7006.2012.02242.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

PMC publication ID

7659374

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339805%20AND%20SRC:MED&resulttype=core&format=json